PDS Biotechnology Corp Net Income (Loss) Available to Common Stockholders, Basic
PDS Biotechnology Corp (PDSB) reported Net Income (Loss) Available to Common Stockholders, Basic of -$13.90 million for the 3-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2018-03-01
- PDS Biotechnology Corp net income (loss) available to common stockholders, basic for the quarter ending 2017-12-31 was -$13.90M.
- PDS Biotechnology Corp net income (loss) available to common stockholders, basic for the quarter ending 2017-09-30 was -$11.28M.
- PDS Biotechnology Corp net income (loss) available to common stockholders, basic for the quarter ending 2017-06-30 was -$13.50M.
- PDS Biotechnology Corp net income (loss) available to common stockholders, basic for the quarter ending 2017-03-31 was -$12.17M.
- PDS Biotechnology Corp net income (loss) available to common stockholders, basic for fiscal 2017 was -$50.86M.
- PDS Biotechnology Corp net income (loss) available to common stockholders, basic for fiscal 2016 was -$38.82M.
- PDS Biotechnology Corp net income (loss) available to common stockholders, basic for fiscal 2015 was -$32.44M.
- PDS Biotechnology Corp net income (loss) available to common stockholders, basic for fiscal 2014 was -$13.78M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | -$13.90M 10-K · filed 2018-03-01 | -$25.19M derived: sum of 2 quarters · filed 2018-03-01 | -$38.69M derived: sum of 3 quarters · filed 2018-03-01 | -$50.86M 10-K · filed 2018-03-01 | |
| 2017-09-30 | -$11.28M 10-K · filed 2018-03-01 | -$24.79M derived: sum of 2 quarters · filed 2018-03-01 | -$36.95M derived: sum of 3 quarters · filed 2018-03-01 | -$46.47M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2017-06-30 | -$13.50M 10-K · filed 2018-03-01 | -$25.67M derived: sum of 2 quarters · filed 2018-03-01 | -$35.19M derived: sum of 3 quarters · filed 2018-03-01 | -$45.95M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2017-03-31 | -$12.17M 10-K · filed 2018-03-01 | -$21.69M derived: sum of 2 quarters · filed 2018-03-01 | -$32.45M derived: sum of 3 quarters · filed 2018-03-01 | -$41.82M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-12-31 | -$9.52M 10-K · filed 2018-03-01 | -$20.27M derived: sum of 2 quarters · filed 2018-03-01 | -$29.65M derived: sum of 3 quarters · filed 2018-03-01 | -$38.82M 10-K · filed 2018-03-01 | |
| 2016-09-30 | -$10.76M 10-K · filed 2018-03-01 | -$10.76M 10-Q · filed 2016-11-01 | -$20.14M derived: sum of 2 quarters · filed 2018-03-01 | -$29.31M 10-Q · filed 2016-11-01 | -$37.36M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | -$9.38M 10-K · filed 2018-03-01 | -$9.38M 10-Q · filed 2016-08-03 | -$18.55M 10-Q · filed 2016-08-03 | -$26.60M derived: sum of 3 quarters · filed 2018-03-01 | -$38.56M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | -$9.17M 10-K · filed 2018-03-01 | -$9.17M 10-Q · filed 2016-05-03 | -$17.23M derived: sum of 2 quarters · filed 2018-03-01 | -$29.19M derived: sum of 3 quarters · filed 2018-03-01 | -$36.45M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | -$8.06M 10-K · filed 2017-03-02 | -$20.02M derived: sum of 2 quarters · filed 2017-03-02 | -$27.28M derived: sum of 3 quarters · filed 2017-03-02 | -$32.44M 10-K · filed 2018-03-01 | |
| 2015-09-30 | -$11.96M 10-K · filed 2017-03-02 | -$11.96M 10-Q · filed 2015-11-06 | -$19.23M derived: sum of 2 quarters · filed 2017-03-02 | -$24.38M 10-Q · filed 2016-11-01 | -$28.04M derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-06-30 | -$7.27M 10-K · filed 2017-03-02 | -$12.42M 10-Q · filed 2016-08-03 | -$16.08M derived: sum of 3 quarters · filed 2017-03-02 | -$19.96M derived: sum of 4 quarters · filed 2017-03-02 | |
| 2015-03-31 | -$5.15M 10-K · filed 2017-03-02 | -$8.81M derived: sum of 2 quarters · filed 2017-03-02 | -$12.70M derived: sum of 3 quarters · filed 2017-03-02 | -$16.07M derived: sum of 4 quarters · filed 2017-03-02 | |
| 2014-12-31 | -$3.66M 10-K · filed 2016-03-08 | -$7.54M derived: sum of 2 quarters · filed 2016-03-08 | -$10.91M derived: sum of 3 quarters · filed 2016-03-08 | -$13.78M 10-K · filed 2017-03-02 | |
| 2014-09-30 | -$3.88M 10-K · filed 2016-03-08 | -$3.88M 10-Q · filed 2015-11-06 | -$7.25M derived: sum of 2 quarters · filed 2016-03-08 | -$10.12M 10-Q · filed 2015-11-06 | |
| 2014-06-30 | -$3.37M 10-K · filed 2016-03-08 | -$6.24M derived: sum of 2 quarters · filed 2016-03-08 | |||
| 2014-03-31 | -$2.87M 10-K · filed 2016-03-08 | ||||
| 2013-12-31 | -$7.96M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |